Development of the Asia Pacific Lupus Collaboration cohort

Kandane-Rathnayake R 1 , Golder V 1 , Louthrenoo W 2 , Luo SF 3 , Jan Wu YJ 3 , Li Z 4 Show all authors , An Y 4 , Lateef A 5 , Sockalingam S 6 , Navarra SV 7 , Zamora L 7 , Hamijoyo L 8 , Katsumata Y 9 , Harigai M 9 , Chan M 10 , O'Neill S 11 , Goldblatt F 12 , Hao Y 13 , Zhang Z 13 , Al-Saleh J 14 , Khamashta M 14 , Takeuchi T 15 , Tanaka Y 16 , Bae SC 17 , Lau CS 18 , Hoi A 1 , Nikpour M 19 , Morand EF 1

Affiliations 

  • 1 School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia
  • 2 Chiang Mai University Hospital, Chiang Mai, Thailand
  • 3 Chang Gung Memorial Hospital, Taipei, Taiwan
  • 4 People's Hospital, Peking University Health Science Center, Beijing, China
  • 5 National University Hospital, Singapore, Singapore
  • 6 University of Malaya, Kuala Lumpur, Malaysia
  • 7 University of Santo Tomas Hospital, Manila, Philippines
  • 8 University of Padjadjaran, Indonesia
  • 9 Tokyo Women's Medical University, Tokyo, Japan
  • 10 Tan Tock Seng Hospital, Singapore, Singapore
  • 11 Rheumatology Liverpool Hospital, SWS Clinical School, UNSW and The Ingham Institute for Applied Medical Research, Liverpool, New South Wales, Australia
  • 12 Royal Adelaide Hospital, Adelaide, New South Wales, Australia
  • 13 Peking University First Hospital, Beijing, China
  • 14 Dubai Hospital, Dubai, United Arab Emirates
  • 15 Keio University School of Medicine, Tokyo, Japan
  • 16 University of Occupational and Environmental Health, Kitakyushu, Japan
  • 17 Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
  • 18 University of Hong Kong, Hong Kong City, Hong Kong
  • 19 St. Vincent's Hospital, Melbourne, Victoria, Australia
Int J Rheum Dis, 2019 Mar;22(3):425-433.
PMID: 30398013 DOI: 10.1111/1756-185X.13431

Abstract

AIM: The aim of this manuscript is to describe the development of the Asia Pacific Lupus Collaboration (APLC) cohort.

METHOD: The APLC cohort is an ongoing, prospective longitudinal cohort. Adult patients who meet either the American College of Rheumatology (ACR) Modified Classification Criteria for systemic lupus erythematosus (SLE), or the Systemic Lupus International Collaborating Clinics (SLICC) Classification Criteria, and provide informed consent are recruited into the cohort. Patients are routinely followed up at 3- to 6-monthly intervals. Information on demographics, clinical manifestations, treatment, pathology results, outcomes, and patient-reported quality of life (Short-form 36 version 2) are collected using a standardized case report form. Each site is responsible for obtaining local ethics and governance approval, patient recruitment, data collection, and data transfer into a centralized APLC database.

RESULTS: The latest APLC cohort comprises 2160 patients with >12 000 visits from Australia, China, Hong Kong, Indonesia, Japan, Malaysia, Philippines, Singapore, Taiwan and Thailand. The APLC has proposed the Lupus Low Disease Activity State (LLDAS) as a treat-to-target (T2T) endpoint, and reported several retrospective and cross-sectional analyses consistent with the validity of LLDAS. Longitudinal validation of LLDAS as a T2T endpoint is currently underway.

CONCLUSION: The APLC cohort is one of the largest contemporary SLE patient cohorts in the world. It is the only cohort with substantial representation of Asian patients. This cohort represents a unique resource for future clinical research including evaluation of other endpoints and quality of care.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications